Biogen's balance sheet as of March 31, 2026 presents a deeply negative liquidation recovery posture for equity, consistent with a pharma company whose carrying value is dominated by intangibles and goodwill that receive zero recovery under liquidation assumptions. Total assets are $29.5B, but the recoverable asset base is materially smaller once haircuts are applied. Cash and cash equivalents of $3.4B recover at 100%. Marketable securities (current $900M, noncurrent $466M) are investment-grade debt instruments recovering near par, approximating $1.37B. Accounts receivable embedded in current assets is not separately broken out in the TAG_CONTEXT but the allowance is only $3M against an implied AR balance derived from working capital less cash, securities, inventory, and other current assets; applying a 90-95% recovery haircut has minimal impact. Inventory of $1.95B current plus $140M noncurrent ($2.09B total) recovers at 60%, yielding approximately $1.25B. PP&E net of accumulated depreciation is $3.0B; at 50-70% recovery, this contributes $1.5B-$2.1B. Intangible assets net of amortization total $9.05B (finite-lived $7.25B plus indefinite-lived approximately $1.8B), and goodwill stands at $6.49B — both recover at 0% under the liquidation lens. Combined intangibles and goodwill total approximately $15.5B, representing the dominant write-down. On the liability side, long-term debt is $6.29B at face value. Current liabilities are $3.0B and include accrued expenses of $2.55B, accounts payable $359M, and taxes payable $94M. Noncurrent liabilities total approximately $1.6B including deferred tax liabilities $484M, operating lease obligations $273M, contingent consideration $267M, and other noncurrent liabilities $787M. The Apellis acquisition, signed March 31, 2026 for $5.6B ($3.6B cash plus $2.0B bank debt), represents a material subsequent-period liability not yet on the March 31 balance sheet. The prior period comparison (December 31, 2025, per the 10-K) shows total assets of approximately $29.3B and notes payable of $6.29B — balance sheet structure largely unchanged quarter-over-quarter. The pending acquisition will substantially reduce the liquid asset buffer ($3.6B of $4.75B total cash and securities earmarked) and add approximately $2.0B new debt, materially worsening the liquidation posture in the next filing period. Estimated liquidation recovery to equity: roughly negative $8-10B, driven entirely by the zero-recovery treatment of $15.5B in intangibles and goodwill against $6.3B face-value debt.
▼ Community Notes